Repare Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Repare TherapeuticsDie Umsatzerlöse und Gewinne des Unternehmens werden voraussichtlich um 7.9% bzw. 16.7% pro Jahr zurückgehen. Der Gewinn pro Aktie wird voraussichtlich zurückgehen um 6.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -54.7% betragen.
Wichtige Informationen
-16.7%
Wachstumsrate der Gewinne
-6.1%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 28.4% |
| Wachstumsrate der Einnahmen | -7.9% |
| Zukünftige Eigenkapitalrendite | -54.7% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 11 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher
Nov 13
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Oct 05Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 19 | -163 | -130 | -125 | 6 |
| 12/31/2025 | 7 | -153 | -116 | -116 | 7 |
| 12/31/2024 | 56 | -92 | -62 | -62 | 8 |
| 9/30/2024 | 67 | -84 | -78 | -77 | N/A |
| 6/30/2024 | 69 | -69 | -80 | -80 | N/A |
| 3/31/2024 | 98 | -46 | -85 | -83 | N/A |
| 12/31/2023 | 51 | -94 | -129 | -127 | N/A |
| 9/30/2023 | 56 | -97 | -128 | -129 | N/A |
| 6/30/2023 | 167 | -3 | -8 | -8 | N/A |
| 3/31/2023 | 137 | -29 | -2 | -1 | N/A |
| 12/31/2022 | 132 | -29 | 0 | 0 | N/A |
| 9/30/2022 | 121 | -26 | 7 | 9 | N/A |
| 6/30/2022 | 8 | -132 | -114 | -112 | N/A |
| 3/31/2022 | 8 | -120 | -103 | -102 | N/A |
| 12/31/2021 | 8 | -107 | -87 | -86 | N/A |
| 9/30/2021 | 1 | -94 | -81 | -78 | N/A |
| 6/30/2021 | 1 | -77 | -69 | -65 | N/A |
| 3/31/2021 | 0 | -62 | -14 | -11 | N/A |
| 12/31/2020 | 0 | -53 | -8 | -6 | N/A |
| 9/30/2020 | N/A | -46 | -4 | -2 | N/A |
| 6/30/2020 | N/A | -40 | 11 | 12 | N/A |
| 3/31/2020 | N/A | -35 | -32 | -31 | N/A |
| 12/31/2019 | N/A | -27 | -20 | -18 | N/A |
| 12/31/2018 | N/A | -14 | -13 | -13 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: RPTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: RPTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: RPTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: RPTXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-7.9% pro Jahr).
Hohe Wachstumseinnahmen: RPTXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-7.9% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: RPTX wird voraussichtlich in 3 Jahren unrentabel sein.